(NASDAQ: FOLD) Amicus Therapeutics's forecast annual revenue growth rate of 21.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Amicus Therapeutics's revenue in 2026 is $598,704,000.On average, 11 Wall Street analysts forecast FOLD's revenue for 2026 to be $235,876,982,781, with the lowest FOLD revenue forecast at $222,502,053,476, and the highest FOLD revenue forecast at $253,660,856,488. On average, 9 Wall Street analysts forecast FOLD's revenue for 2027 to be $279,142,642,218, with the lowest FOLD revenue forecast at $255,798,993,976, and the highest FOLD revenue forecast at $305,204,471,017.
In 2028, FOLD is forecast to generate $335,993,033,772 in revenue, with the lowest revenue forecast at $306,052,938,274 and the highest revenue forecast at $356,664,781,488.